uniQure N.V. (LON:0EE0)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.36B +138.0% |
| Revenue (ttm) | 13.70M -10.4% |
| Net Income | -158.18M |
| EPS | -2.64 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,318 |
| Average Volume | 8,696 |
| Open | 29.15 |
| Previous Close | 29.19 |
| Day's Range | 27.82 - 31.00 |
| 52-Week Range | 7.50 - 71.16 |
| Beta | 0.87 |
| RSI | 72.69 |
| Earnings Date | May 5, 2026 |
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial numbers in USD Financial StatementsNews
uniQure price target lowered to $50 from $70 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on uniQure (QURE) to $50 from $70 and keeps a Buy rating on the shares after the company reported Q1…
uniQure price target raised to $28 from $14 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $28 from $14 and keeps a Buy rating on the shares. The firm reiterated its Buy view…
uniQure Earnings Call Transcript: Q1 2026
Q1 2026 saw increased revenue and reduced R&D expenses, with a strong cash position supporting operations into 2029. Regulatory progress for AMT-130 in the U.K. and U.S. continues, while AMT-191 and AMT-260 advance in clinical development. AMT-162 was discontinued due to safety concerns.
uniQure reports Q1 EPS (85c), consensus (75c)
Reports Q1 revenue $3.56M, consensus $4.49M. “During the first quarter of 2026, we remained focused on advancing AMT-130 to patients globally as rapidly as possible while executing across our broader…
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
uniQure price target raised to $37 from $31 at Chardan
Chardan raised the firm’s price target on uniQure (QURE) to $37 from $31 and keeps a Buy rating on the shares. The firm cites the company announcement that, following a…
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
uniQure to Announce First Quarter 2026 Financial Results
~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure price target raised to $10 from $9 at Goldman Sachs
Goldman Sachs raised the firm’s price target on uniQure (QURE) to $10 from $9 and keeps a Neutral rating on the shares.
uniQure call volume above normal and directionally bullish
Bullish option flow detected in uniQure (QURE) with 4,415 calls trading, 1.5x expected, and implied vol increasing almost 7 points to 157.70%. May-26 30 calls and Apr-26 16 calls are…
uniQure put volume heavy and directionally bearish
Bearish flow noted in uniQure (QURE) with 5,627 puts trading, or 9x expected. Most active are Apr-26 15 puts and Apr-26 16 calls, with total volume in those strikes near…
uniQure put volume heavy and directionally bearish
Bearish flow noted in uniQure (QURE) with 1,015 puts trading, or 2x expected. Most active are Apr-26 15 puts and May-26 15 puts, with total volume in those strikes near…
uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims
A class action lawsuit was filed against uniQure ($QURE) on February 10, 2026. Plaintiffs -investors- in the federal securities class action allege that they acquired uniQure stock at artificially inf...
uniQure price target lowered to $25 from $31 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on uniQure (QURE) to $25 from $31 and keeps an Equal Weight rating on the shares. While Vinay Prasad’s departure from…
uniQure upgraded to Outperform from Neutral at Mizuho
Mizuho upgraded uniQure (QURE) to Outperform from Neutral with a price target of $35, up from $12.
uniQure upgraded at Mizuho on potential improvement in regulatory outlook
As previously reported, Mizuho upgraded uniQure (QURE) to Outperform from Neutral with a price target of $35, up from $12, arguing that Friday’s “unexpected” announcement that Dr. Vinay Prasad will…
uniQure shares positioned for ‘value inflection,’ says H.C. Wainwright
H.C. Wainwright says the departure of Center for Biologics Evaluation and Research Director Vinay Prasad at the end of April “reshapes the regulatory calculus” for uniQure’s (QURE) AMT-130. H.C. Wainw...
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying
Federal health officials, facing criticism from lawmakers for recent rejections of rare-disease drugs, attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment ...
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease
UniQure needs to run another study to prove its gene therapy "actually helps people with Huntington's disease," a senior FDA official said. The official said UniQure is the "latest company to make a f...
Sr. FDA official calls Uniqure's Huntington's disease treatment a failure
A senior FDA official called Uniqure's experimental Huntington's disease treatment a "failed product" in a conference call with media members on Thursday, casting further doubt on the pr...
FDA official says UniQure fell short on Huntington's trial, defends new study request
UniQure's , trial design for its gene therapy for Huntington's disease did not offer sufficient proof that the drug slowed disease progression, a top U.S. Food and Drug Administration official said o...
uniQure Transcript: TD Cowen 46th Annual Health Care Conference
Phase I/II data for Huntington's showed significant slowing of disease progression and a strong safety profile, but FDA requires a new phase III trial due to concerns over post hoc analyses. Early results in epilepsy and Fabry programs are promising, with further data and regulatory discussions expected in 2024.
uniQure Earnings Call Transcript: Q4 2025
Full-year 2025 revenue declined to $16.1M, with a strong cash position of $622.5M supporting operations into 2029. AMT-130 for Huntington's disease showed robust 3-year efficacy data, but faces regulatory hurdles as the FDA requires a Phase III sham-controlled trial.
FDA tells UniQure study data insufficient for brain disorder therapy application
UniQure said on Monday the U.S. Food and Drug Administration has told the company that its data from an early-to-mid stage trial would not support a marketing application for its brain disorder gene t...